StocksMedium•13 November 2026•
1 min read
Milestone Pharmaceuticals Reports Q3 Results and Launches Cost-Efficiency Plan
Key Facts
1Milestone Pharmaceuticals reported Q3 2026 financial results featuring steady prescription growth for its CARDAMYST nasal spray.
2The company announced cost-efficiency measures designed to extend its cash runway through the release of Phase 3 data for AFib-RVR.
Milestone Pharmaceuticals reported its Q3 2026 financial results featuring steady prescription growth for its CARDAMYST nasal spray. The company said in a statement via GlobeNewswire that it has launched cost-efficiency measures designed to extend its cash runway through the release of Phase 3 data for its AFib-RVR treatment.
MIST closed at $0.6552 on November 12, 2026, prior to the announcement of the capital preservation strategy. The company aims to ensure sufficient cash resources to reach its clinical milestones while continuing to support the commercial rollout of CARDAMYST.